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Abstract
Background and Aims: Previous studies have shown that antidepressants reduce inflammation in 
animal models of colitis. The present trial aimed to examine whether fluoxetine added to standard 
therapy for Crohn’s disease [CD] maintained remission, improved quality of life [QoL] and/or 
mental health in people with CD as compared to placebo.
Methods: A parallel randomized double-blind placebo controlled trial was conducted. Participants 
with clinically established CD, with quiescent or only mild disease, were randomly assigned to 
receive either fluoxetine 20 mg daily or placebo, and followed for 12 months. Participants provided 
blood and stool samples and completed mental health and QoL questionnaires. Immune functions 
were assessed by stimulated cytokine secretion [CD3/CD28 stimulation] and flow cytometry for 
cell type. Linear mixed-effects models were used to compare groups.
Results: Of the 26 participants, 14 were randomized to receive fluoxetine and 12 to placebo. Overall, 
14 [54%] participants were male. The mean age was 37.4 [SD=13.2] years. Fluoxetine had no effect 
on inflammatory bowel disease activity measured using either the Crohn’s Disease Activity Index 
[F(3, 27.5)=0.064, p=0.978] or faecal calprotectin [F(3, 32.5)=1.08, p=0.371], but did have modest 
effects on immune function. There was no effect of fluoxetine on physical, psychological, social or 
environmental QoL, anxiety or depressive symptoms as compared to placebo [all p>0.05].
Conclusions: In this small pilot clinical trial, fluoxetine was not superior to placebo in maintaining 
remission or improving QoL. [ID: ACTRN12612001067864.]
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1. Introduction
There is ongoing debate regarding the efficacy of antidepressants 
for mental disorders;1 however, antidepressants have been increas-
ingly studied in the context of physical health and, in particular, the 
immune system. Although studies with healthy volunteers have dem-
onstrated that antidepressants can improve immunoregulatory activ-
ity,2 lead to a reduction in the need for steroids in asthma sufferers3 
and to further possible improvements in overall immune function,4 
little research has been conducted on antidepressants in inflamma-
tory bowel disease [IBD].
It has been documented that up to 30% of IBD patients use 
antidepressants.5 In the initial systematic review conducted on the 
topic,6 the low quality of available evidence made it impossible to 
provide a definitive statement on their efficacy in IBD. The most 
recent update to this review7 suggested a positive impact of anti-
depressants [desipramine and fluoxetine] on inflammation in IBD. 
This evidence originates from randomized controlled trials [RCTs] in 
animal models of IBD where desipramine and fluoxetine reduced the 
severity of intestinal inflammation. Most recently, a small 12-week 
RCT compared duloxetine [60 mg/day] to placebo in patients with 
IBD and demonstrated a slight improvement in anxiety and depres-
sion [p=0.049 and 0.041, respectively], improvements in physical, 
psychological and social quality of life [QoL] [p=0.001, 0.038 and 
0.015, respectively] and decreased IBD severity [p=0.02], with mild 
to moderate effect sizes.8 However, the long-term impact of anti-
depressant treatment on IBD course or other clinical outcomes is 
largely unknown. Additionally, there is no experimental study using 
objective measures of inflammation such as faecal calprotectin [FC] 
or inflammatory markers in blood. Thus, the aim of the present 
study was to examine the impact of a low-dose antidepressive agent, 
fluoxetine, in addition to standard therapy as compared to placebo 
on disease activity, QoL and mental health in patients with Crohn’s 
disease [CD] over 12 months.
2. Methods
The study was approved by the hospitals’ and university research eth-
ics committees. The protocol was registered with the Australian New 
Zealand Clinical Trials Registry [ID: ACTRN12612001067864]. 
Adult patients from two major South Australian hospitals with clini-
cally established diagnosis of CD, in clinical remission but who flared 
CD in the last 12 months were included in this parallel double-blind 
placebo RCT involving intention to treat analyses. We excluded those 
with serious uncontrolled mental illness, those alcohol/substance-
dependent or cognitively impaired; those taking antidepressants or 
receiving psychotherapy; those taking steroids [prednisolone >15 mg 
or equivalent]; those pregnant/breastfeeding or planning to become 
pregnant; and those taking any medications listed as contraindicated 
with fluoxetine.9 Participants were randomly [using a computer-gen-
erated sequence] assigned to receive either fluoxetine 20 mg daily or 
placebo [i.e. gelatin capsules filled with microcrystalline cellulose]. 
Fluoxetine was selected based on previous research showing its 
anti-inflammatory properties in humans,10,11 and in relation to IBD 
based on animal models of colitis.7,12 While desipramine has shown 
similar effects with respect to reduced inflammation, fluoxetine is 
a better tolerated medication, with fewer adverse events. Previous 
human studies have recommended a dose of 20 mg daily when look-
ing for anti-inflammatory effect and the length of the study to be at 
least 3–8 weeks.10,11,13–15 Patients in both treatment arms remained 
on their current IBD medication. Treatment was delivered via hos-
pital pharmacies to ensure double blinding. Participants were asked 
to provide blood and stool samples and complete questionnaires 
on four occasions [baseline, 3, 6 and 12 months] [Appendix 1]. 
Screening for mental disorders was undertaken using the Structural 
Clinical Interview for DSM disorders [SCID].16 The primary out-
come measures were a significant group difference in the CD 
remission rate as measured on the Crohn’s Disease Activity Index 
[CDAI]17 [cut-off <150] and the difference in means on the World 
Health Organisation Quality of Life questionnaire [WHOQoL].18 
Secondary measures were differences in: remission rates as measured 
by FC;19 means on the Hospital Anxiety Depression Scale [HADS];20 
and mean cytokine and chemokine levels between the experimental 
and control groups at 6 months. Peripheral blood mononuclear cells 
[PBMCs] were isolated from fresh blood by density centrifugation as 
previously described.21,22 Power calculations were prepared for two 
main outcome measures of disease activity and QoL, using the PASS 
11 software package:
[a] Disease activity on CDAI at 12 months: a sample size of 26 in 
each group yields 80% power to detect a difference in means of 
65 assuming a common standard deviation of 70 using a two 
group t-test with a 0.025 two-sided significance level. A value of 
p=0.025 was used to allow for multiple testing.
[b] Quality of life on WHOQoL at 12 months: a sample size of 23 
in each group yields 80% power to detect a difference in means 
of 19 assuming a common standard deviation of 20 using a two 
group t-test with a 0.025 two-sided significance level. A value of 
p=0.025 was used to allow for multiple testing.
Groups were compared on the outcome measures [except for 
immune studies] using the linear mixed effects, with time, group and 
time–group interaction terms included, adjusting for stratifying vari-
ables [sex, HADS score]. Immune cell proportion and cytokine secre-
tion were compared by paired Student’s t-test.
3. Results
The CONSORT flow diagram [Figure 1] presents study recruitment. 
Overall, 26 patients were randomized: 14 to fluoxetine and 12 to 
placebo groups. In each group, three participants withdrew from 
the study at some point, resulting in an overall attrition of 23%. 
Table 1 presents demographic, clinical and treatment characteristics 
of the study’s population. The mean age was 37.4 [SD=13.2] years. 
Throughout the trial, the fluoxetine group received numerically more 
biologics than controls [at 6 months: n=9 vs n=3 and at 12 months: 
n=8 vs n=3, respectively, p=n.s.]. The numbers of patients taking 
immunomodulators were similar between the fluoxetine group and 
controls [at 6 months: n=9 vs n=6 and at 12 months: n=8 vs n=7]. 
The use of steroids was low, with only one control group partici-
pant taking them at 6 months and no participants taking them at 
12 months.
3.1. Fluoxetine and disease activity
There was no statistically significant difference in the proportion 
of participants in remission at any time point [p<0.05] [Table  2]. 
Putting the CDAI into the linear mixed-effects model as a continu-
ous variable likewise showed no group difference [F(3, 27.5)=0.064, 
p=0.978].
While numerically the fluoxetine group had slightly better dis-
ease control during the study, as assessed by FC, multivariate group 
comparions showed no group difference in FC scores during the 
12-month treatment period [F(3, 32.5)=1.08, p=0.371].
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Live PBMC single cells were gated [Table 3]. Fluoxetine treatment 
significantly increased the proportion of TH Effector Memory and decreased 
the proportion of TC Effector Memory RA cells at the 6-month visit, while pla-
cebo treatment had no effect [Table 4]. Other T cell subpopulations in 
the peripheral blood, including TH and TC gut homing and TREG, did 
not vary in response to either fluoxetine or placebo between baseline 
and 6  months. Placebo patients had significantly reduced interleu-
kin-10 [IL-10] secretion from PBMCs at 6 months compared to base-
line, while fluoxetine patients had no such effect [Table 5]. No other 
cytokine stimulation response was affected by fluoxetine or placebo.
3.2 Fluoxetine, QoL and metal health
There was no significant group difference in physical QoL [F(3, 
34.9)=0.560, p=0.645], psychological QoL [F(3, 33.5)=0.217, p=0.884], 
social relationships QoL [F(3, 33.7)=0.553, p=0.649] or environmental 
QoL [F(3, 36.1)=0.031, p=0.992] over the 12 months. There was no 
significant group difference in anxiety [F(3, 33.9)=0.063, p=0.979] or 
depression [F(3, 36.1)=0.106, p=0.956] over the 12 months.
3.3. Safety
Overall, eight [57%] fluoxetine group participants versus three 
[25%] controls reported side-effects. These all resolved during 
the first 2 weeks of treatment. In the fluoxetine group, side-effects 
included: fatigue [n=4], episode of low mood/anxiety [n=2]; nausea/
diarrhoea/vomiting [n=2], dry mouth [n=1] and hot flushes [n=1] [n 
adds to >8 as some participants reported more than one side-effect]. 
In the placebo group, these were muscle spasms [n=2] and nausea/
diarrhoea/vomiting [n=1].
CONSORT Flow Diagram
Assessed for eligibility (n=818)
Excluded (n=788)
Not meeting inclusion criteria (n=262)
Declined to participate (n=157)
Other reasons (n=74) - due to
distance or have requested no research 
Not responded to rst or 2nd invite 
letters (n=295)
Analysed (n=11)
Excluded from analysis (give reasons) (n=3)
– missing data 
Lost to follow-up (give reasons) (n=3) –
withdrew from study
Discontinued intervention (give reasons) (n=3)
– no reason (n=1)
– side effects (n=1)
– IBD are (n=1)
Allocated to uoxetine (n=14)
Received allocated intervention (n=13)
Did not receive allocated intervention (give 
reasons) (n=1)
– not contactable (n=1)
Lost to follow-up (give reasons) (n=3) –
withdrew from study
Discontinued intervention (give reasons) (n=2)
– pregnancy (n=1)
– no reason (n=1)
– moved interstate (n=1)
Allocated to placebo (n=12) 
Received allocated intervention (n=10)
Did not receive allocated intervention (give
reasons) (n=2) 
– moved interstate (n=1)
– not contactable (n=1)
Analysed (n=9)
Excluded from analysis (give reasons) (n=3)
– missing data 
Allocation
Analysis
Follow-Up
Randomized (n=26)
Enrollment
Recruited (n=30)
Withdrew prior to randomisation 
(n=4) 
Relapsing mental illness (n=2)♦
♦ Not contactable for an interview 
(n=2)
♦
♦
♦ ♦
♦
♦
♦
♦
♦
♦
Figure 1. CONSORT flow diagram of study recruitment.
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4. Discussion
This study is the first longitudinal trial on the effect of fluoxetine on 
CD activity, QoL and mental health.
While a previous trial of a similar size to ours demonstrated 
short-term effectiveness of duloxetine in improving anxiety, 
depression, QoL and severity of symptoms measured on a dis-
ease activity index,8 the present trial demonstrated no benefit of 
fluoxetine on disease activity [assessed with CDAI and FC], QoL 
or mental health over 12 months compared to placebo. This may 
mean that selective serotonin reuptake inhibitors such as fluox-
etine offer no IBD-specific benefit while other newer antidepres-
sants could be a more promising treatment pathway. Given the 
success of tricyclic antidepressants in managing functional gut 
disorders,23,24 they are certainly an interesting option to explore. 
Similarly, atypical medications such as mirtazapine, which resem-
ble tricyclics in their mechanism of action but have fewer side-
effects, could also be tested. However, it should be noted that 
this result could also be due to a small sample size. In addition, 
participants were allowed to receive their usual treatment [ster-
oids, biologics, etc.] and these could be increased during the trial, 
if needed. While relapse of CD meant withdrawal from the study, 
some patients had mildly active disease throughout the trial and 
may have received more aggressive treatment for it [e.g. at base-
line and throughout the trial numerically more patients in the 
fluoxetine group received biologics], which could impact our 
results, particularly that biologics are known to improve QoL in 
IBD and thus also potentially mood.25 Further, clinical depression 
Table 2. Disease activity over time by group: n [%]
Fluoxetine (n=14) Placebo (n=12)
Baseline 
(n=14)
3 months 
(n=12)
6 months 
(n=11)
12 months 
(n=10)
Baseline 
(n=12)
3 months 
(n=10)
6 months 
(n=10)
12 months 
(n=8)
CDAI Active >150 0 [0] 0 [0] 0 [0] 1 [10] 0 [0] 1 [10] 0 [0] 0 [0]
Calprotectin Active >200 0 [0] 3 [25] 1 [9.1] 1 [10] 2 [16.6] 4 [40] 5 [50] 0 [0]
Mean [SD]
CDAI 63.8 [44.4] 54.92 [37.3] 52.36 [43.3] 84.40 [82.5] 66.4 [44.7] 53.1 [59.7] 48.50 [39.2] 60.63 [46.5]
Calprotectin 46.4 [33.2] 125.5 [106.6] 91.4 [86.1] 76.9 [90.5] 98.1 [94.4] 178.3 [108.9] 185.4 [111.8] 67.9 [45.6]
Physical QoL 24.8 [5.3] 25.4 [3.4] 25.7 [4.5] 26.3 [3.7] 26 [4.3] 27.2 [2.9] 26 [4.6] 25.7 [6.1]
Psychological QoL 22.3 [4.1] 24.5 [2.6] 23.7 [4.2] 24.1 [3.6] 22.8 [3.7] 24.3 [2.2] 23.9 [2.3] 23.3 [4.1]
Social QoL 10.4 [2.9] 11.1 [3.1] 11.4 [2.4] 11.8 [2.2] 12.3 [2.1] 12.3 [1.1] 12.3 [1.1] 12 [2.8]
Environmental QoL 31.5 [4.8] 31.7 [4.1] 32.3 [4.6] 31.6 [4.6] 32.2 [4.4] 32.2 [3.8] 32.8 [4.5] 32.2 [3.1]
HADS Anxiety 5.3 [4.1] 3.2 [2.5] 3.2 [2.6] 3.8 [2.6] 4.9 [3.4] 2.9 [2.1] 3.3 [2.9] 4.2 [4.9]
HADS Depression 3.8 [2.9] 2 [1.6] 2.7 [2.9] 2.9 [2.8] 3.6 [3.1] 1.7 [1.8] 2 [1.9] 3.1 [3.4]
Table 3. Flow cytometry gating strategy
Cell type Gating strategy
T CD3+
THELPER [TH] CD3+ CD4+ CD8−
TH gut homing CD3+ CD4+ CD8− CD45RA− CD49d+ β7+
TH Effector Memory [TH EM] CD3+ CD4+ CD8− CD45RA− CD197−
TH Central Memory [TH CM] CD3+ CD4+ CD8− CD45RA− CD197−,
TH Effector Memory RA [TH EMRA] CD3+ CD4+ CD8− CD45RA− CD197−
TREG CD3+ CD4+ CD8− CD25+ CD127
DIM
TCYTOTOXIC [TC] CD3+ CD4− CD8+
TC gut homing CD3+ CD4− CD8+ CD45RA− CD49d+ β7+
TC Effector Memory [TC EM] CD3+ CD4− CD8+ CD45RA− CD197−
TC Central Memory [TC CM] CD3+ CD4− CD8+ CD45RA− CD197−,
TC Effector Memory RA [TC EMRA] CD3+ CD4− CD8+ CD45RA− CD197−
Table 1. Demographic, clinical and treatment characteristics by group: n [%]
Fluoxetine (n=14) Placebo (n=12)
Gender Male 8 [57] 6 [50]
Marital status Married/de facto 8 [57] 9 [75]
Employment status Working full- or part-time 10 [71] 9 [75]
Education University degree 5 [36] 6 [50]
Year 12 4 [29] 2 [17]
Operations for IBD 7 [50] 7 [58]
Medication for IBD Complementary 7 [50] 5 [42]
Mesalazine 4 [29] 3 [25]
Prednisolone 1 [7] 0 [0]
Immunomodulators 9 [64] 10 [83]
Biologics 9 [64] 4 [33]
Analgesics 5 [36] 5 [42]
Currently smoking 3 [21] 2 [17]
Previous antidepressant use 3 [21] 1 [8]
Previous psychotherapy use 3 [21] 3 [25]
Any overnight hospital admissions for IBD 11 [79] 9 [75]
Mean [SD]
Age, years 38.07 [13.6] 36.67 [13.2]
Years since diagnosis with CD 14.98 [13.1] 12.21 [8.1]
No. of hospital admissions in last 5 years 3.44 [2.3] 3.08 [4.1]
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was not necessary to enter the trial and it could be argued that 
if the pathway to controlling disease activity in CD leads via 
improving mood, as could be supposed based on the current 
brain–gut–microbiome research reviewed elsewhere,26–28 to show 
the effect we should have included only those CD patients with 
established depression. The mechanism behind the antidepres-
sants’ effect on inflammation is, however, as yet unclear. Similarly, 
it could be easier to show antidepressants’ effect on inflammation 
had we included people during flares. However, in the present 
trial we were interested in the maintenance of remission and thus 
that was not considered appropriate.
Adaptive T cell immune responses have a central role in IBD, 
and fluoxetine treatment had modest, but significant, effects on 
effector memory RA cells, increasing TH and decreasing TC popu-
lations. These cells have important roles in immune responses to 
virus and vaccine, and while they are yet to be definitively char-
acterized in IBD they are likely to play an important role.29 There 
was no effect on the proportions of TREG or the proportions of 
TH or TC expressing integrins that direct T cells to migrate to the 
gut. Interestingly, T-cell secreted IL-10 decreased in the placebo 
group but not the fluoxetine group. IL-10 plays an important 
anti-inflammatory role, and the sustained IL-10 secretion that 
occured in the fluoxetine-treated group but not placebo group 
suggests that fluoxetine activates anti-inflammatory mechanisms. 
However, as there was little difference between clinical symptoms 
associated with placebo or fluoxetine treatment, other compensa-
tory immune mechanisms may be in play, potentially involving 
TEMRA cells.
Finally, the current study showed that the intervention was 
acceptable to patients and was well tolerated. Clinicians may thus 
use fluoxetine in the IBD population.
4.1. Limitations
While attrition was not particularly high, recruitment proved 
challenging and the study was underpowered. In order to be suc-
cessful with the trial of antidepressants in IBD, a multi-centre 
approach with a large pool of patients not exposed to antidepres-
sants is required. Future studies should utilize objective measures 
of inflammation such as FC and inflammatory markers in blood 
and follow patients for at least 12 months. If the sample size allows 
for it, confounders such as concurrent depression, previous use of 
antidepressants and current CD treatment [e.g. biologics] should 
be controlled for.
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Table 4. Flow cytometry analysis of T cell populations in PBMCs from subjects who received placebo and active treatment. Study entry and 
6-month visit relative proportions compared by paired t-test. n.s. = p>0.05, *p<0.05. Populations gated as outlined in Table 3.
Cell type Fluoxetine Placebo
[%] Study entry 6 months Significance Study entry 6 months Significance
T 71.2 ± 3.3 70.9 ± 2.8 n.s. 72.4 ± 1.9 66.2 ± 1.74 n.s.
TH 65.1 ± 3.4 66.6 ± 3.6 n.s. 63.1 ± 3.2 61.3 ± 3.7 n.s.
TH α4β7 10.7 ± 1.2 11.2 ± 1.3 n.s. 12.3 ± 2.3 14.0 ± 2.1 n.s
TH EM 6.7 ± 0.6 7.2 ± 0.9 n.s. 8.1 ± 1.8 6.8 ± 1.1 n.s.
TH CM 2.5 ± 0.4 2.5 ± 0.37 n.s. 3.3 ± 0.7 3.3 ± 0.8 n.s.
TH EMRA 42.8 ± 4.5 45.8 ± 4.5 * ↑ 44.0 ± 2.9 39.7 ± 3.1 n.s.
TREG 3.6 ± 0.53 4.3 ± 0.7 n.s. 4.2 ± 0.7 3.6 ± 0.4 n.s.
TC 23.5 ± 2.1 23.5 ± 1.9 n.s. 20.3 ± 2.8 22.3 ± 3.9 n.s.
TC α4β7 27.5 ± 2.4 29.2 ± 2.3 n.s. 32.8 ± 2.8 32.2 ± 3.8 n.s.
TC EM 3.9 ± 0.4 3.9 ± 0.4 n.s. 3.2 ± 0.5 3.3 ± 0.9 n.s.
TC CM 27.6 ± 2.5 27.0 ± 2.0 n.s. 27.3 ± 4.3 27.8 ± 5.3 n.s.
TC EMRA 3.9 ± 0.5 3.5 ± 0.48 * ↓ 4.4 ± 0.9 4.75 ± 0.9 n.s.
Table 5. Comparison of CD3/CD28 stimulated cytokine concentrations in PBMC supernatants from subjects who received placebo and ac-
tive treatment. Visit 1 [V1] and visit 2 [V2] concentrations compared by paired t-test. n.s. = p>0.05, *p<0.05.
Cytokine [pg/ml] Fluoxetine Placebo
Study entry 6 months Significance Study entry 6 months Significance
IFN-γ 33 677 ± 10 741 25 074 ± 7565 n.s. 19 576 ± 6946 6364 ± 2012 n.s.
IL-2 16 052 ± 1199 13 542 ± 2234 n.s. 10 477 ± 2640 9961 ± 2788 n.s.
IL-4 0.875 ± 0.142 0.641 ± 0.09 n.s. 0.471 ± 0.14 0.299 ± 0.06 n.s.
IL-5 1256 ± 230.7 952.6 ± 175.3 n.s. 711.2 ± 214.3 553.7 ± 176.5 n.s.
IL-6 783.3 ± 212.2 1075 ± 615 n.s. 675.1 ± 257.3 206.1 ± 79.43 n.s.
IL-10 801.52 ± 171.2 525.3 ± 93.2 n.s. 633.6 ± 163.3 222.9 ± 63.2 * ↓
IL-13 9289 ± 1064 6697 ± 970.7 n.s. 4369 ± 1091 3182 ± 885.8 n.s.
TNF-α 6649 ± 541.7 5671 ± 730.9 n.s. 4593 ± 1113 3269 ± 929.3 n.s.
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